205 related articles for article (PubMed ID: 30838820)
1. Medullary Thyroid Carcinoma: Prognostic Variables And Tumour Markers Affecting Survival.
Hassan A; Siddique M; Riaz S; Khan AI; Nawaz MK; Bashir H
J Ayub Med Coll Abbottabad; 2018; 30(Suppl 1)(4):S627-S632. PubMed ID: 30838820
[TBL] [Abstract][Full Text] [Related]
2. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH
Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
4. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels.
Fanget F; Demarchi MS; Maillard L; Lintis A; Decaussin M; Lifante JC
Br J Surg; 2021 Sep; 108(9):1064-1071. PubMed ID: 33899100
[TBL] [Abstract][Full Text] [Related]
5. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
[TBL] [Abstract][Full Text] [Related]
6. PROGNOSTIC VARIABLES AFFECTING PRIMARY TREATMENT OUTCOME FOR MEDULLARY THYROID CANCER.
Momin S; Chute D; Burkey B; Scharpf J
Endocr Pract; 2017 Sep; 23(9):1053-1058. PubMed ID: 28683235
[TBL] [Abstract][Full Text] [Related]
7. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
8. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
[TBL] [Abstract][Full Text] [Related]
9. An Overview of Medullary Thyroid Cancer Cases Treated at Kuwait Cancer Control Center.
Shete J; AlSaleh K; Safwat R; Bedair A; ElSherify M; Hussein A; Nazeeh M; Mohanty A
Gulf J Oncolog; 2020 Sep; 1(34):39-47. PubMed ID: 33431361
[TBL] [Abstract][Full Text] [Related]
10. Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma?
Bümming P; Ahlman H; Nilsson B; Nilsson O; Wängberg B; Jansson S
Langenbecks Arch Surg; 2008 Sep; 393(5):699-703. PubMed ID: 18626656
[TBL] [Abstract][Full Text] [Related]
11. Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.
Guo F; Fu G; Li F; Hua Y; Wang Z; Zheng X; Zhao J; Gao M
World J Surg Oncol; 2024 May; 22(1):121. PubMed ID: 38711029
[TBL] [Abstract][Full Text] [Related]
12. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
13. CALCITONIN SECRETORY INDEX AND UNSUSPECTED NODAL DISEASE IN MEDULLARY THYROID CARCINOMA.
Filimon S; Payne RJ; Black MJ; Hier MP; Mlynarek AM; Forest VI; Tamilia M
Endocr Pract; 2018 May; 24(5):460-467. PubMed ID: 29847167
[TBL] [Abstract][Full Text] [Related]
14. Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening.
Torresan F; Mian C; Cavedon E; Iacobone M
Langenbecks Arch Surg; 2019 Jun; 404(4):411-419. PubMed ID: 30903267
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF;
J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
Łacka K; Michałek K; Majewski P
Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
[TBL] [Abstract][Full Text] [Related]
17. Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma.
Yip DT; Hassan M; Pazaitou-Panayiotou K; Ruan DT; Gawande AA; Gaz RD; Moore FD; Hodin RA; Stephen AE; Sadow PM; Daniels GH; Randolph GW; Parangi S; Lubitz CC
Surgery; 2011 Dec; 150(6):1168-77. PubMed ID: 22136837
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin doubling time in medullary thyroid carcinoma after the detection of distant metastases keenly predicts patients' carcinoma death.
Ito Y; Miyauchi A; Kihara M; Kudo T; Miya A
Endocr J; 2016 Jul; 63(7):663-7. PubMed ID: 27097545
[TBL] [Abstract][Full Text] [Related]
19. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
20. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
